2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity - sprookjes - yvandenbroek - TriplyDB

2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity

2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity

http://www.wikidata.org/entity/Q27619603

about

Onto better TRAILs for cancer treatment Principles of antibody-mediated TNF receptor activation Crystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity Crystal structure of the extracellular domain of mouse RANK ligand at 2.2-A resolution Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5 Structure of the Chlamydia trachomatis Immunodominant Antigen Pgp3 Overview of protein structural and functional folds.The methionine-aromatic motif plays a unique role in stabilizing protein structure.Possible novel therapy for malignant gliomas with secretable trimeric TRAIL.TNF alpha and the TNF receptor superfamily: structure-function relationship(s).Advances in Viral Vector-Based TRAIL Gene Therapy for Cancer.The transmembrane domains of TNF-related apoptosis-inducing ligand (TRAIL) receptors 1 and 2 co-regulate apoptotic signaling capacity.Progranulin-derived Atsttrin directly binds to TNFRSF25 (DR3) and inhibits TNF-like ligand 1A (TL1A) activity.The TRAIL to viral pathogenesis: the good, the bad and the ugly TNF superfamily protein-protein interactions: feasibility of small- molecule modulation Variants of Osteoprotegerin Lacking TRAIL Binding for Therapeutic Bone Remodeling in Osteolytic Malignancies.DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.An optimized antibody-single-chain TRAIL fusion protein for cancer therapy.Physapubescin selectively induces apoptosis in VHL-null renal cell carcinoma cells through down-regulation of HIF-2α and inhibits tumor growth TRAIL gene therapy: from preclinical development to clinical application.TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment.Resistance to TRAIL and how to surmount it.Regulation of the human TRAIL gene.Role of pancreatic β-cell death and inflammation in diabetes.Interleukin-10 up-regulates tumour-necrosis-factor-alpha-related apoptosis-inducing ligand (TRAIL) gene expression in mammary epithelial cells at the involution stage.Death ligands and granulysin: mechanisms of tumor cell death induction and therapeutic opportunities.Preparation and characterization of a novel variant of human tumor necrosis factor-related apoptosis-inducing ligand from the rhesus monkey, Macaca mulatta.A genetically encoded multifunctional TRAIL trimer facilitates cell-specific targeting and tumor cell killing.The extracellular matrix glycoprotein elastin microfibril interface located protein 2: a dual role in the tumor microenvironment.Cancer gene therapy using a novel secretable trimeric TRAIL.Human menstrual blood-derived mesenchymal stem cells as a cellular vehicle for malignant glioma gene therapy Crystallization and preliminary X-ray crystallographic study of the extracellular domain of the 4-1BB ligand, a member of the TNF family.Functional analysis of tumour necrosis factor-alpha-related apoptosis-inducing ligand (TRAIL): cysteine-230 plays a critical role in the homotrimerization and biological activity of this novel tumoricidal cytokine.Hypoxic resistance to articular chondrocyte apoptosis--a possible mechanism of maintaining homeostasis of normal articular cartilage.Resistance of mitochondrial DNA-deficient cells to TRAIL: role of Bax in TRAIL-induced apoptosis.Association of human tumor necrosis factor-related apoptosis inducing ligand with membrane upon acidification.Interferon-activated neutrophils store a TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) intracellular pool that is readily mobilizable following exposure to proinflammatory mediators.Death Receptors: New Opportunities in Cancer Therapy.

P2860

Q26768160-E986E1E0-8F58-4860-BC7C-E5105C5825E8 Q26796270-0CBC616C-29E7-4CD0-A091-8E70EEAAD15C Q27625357-92AC2B6F-0B9F-42E9-84AA-99DCDBF8B90D Q27635130-BB9FD72D-43F4-4F7C-8749-DACFD50A7A80 Q27636573-325E9057-8F5B-4E61-93AF-0621B5E2BA28 Q27649718-D08EF748-9BF8-4622-9DD3-AEFC0B924AB5 Q27678279-CEE58790-8DCB-4762-904A-18DDFC126A89 Q30368988-8A440CE3-0F2A-4709-9CFC-59A021D37E7C Q30420005-10B65E61-C345-4B87-92CE-C91FB33EFBF6 Q33410831-76912500-12DF-4184-AB82-DF31FACCC8FA Q33909217-C1010D1F-FD7C-4550-9B53-71B4639E0F60 Q34384021-1E8A9B04-A453-4720-B8B0-8205C1338592 Q34390877-BAACB0FA-46AB-4604-B831-1BCDFDE37233 Q35126225-FEA6F711-40EF-4EFC-97D3-7325C7FE2666 Q35146349-B74DD222-23E5-4444-AEAF-A5B174C1B720 Q35534271-B55E1F76-CDC8-48EF-A6C7-A680933783FB Q35611366-ECB84A12-1769-4A3D-B40C-ECA6F7ECB05F Q36215003-D9595DFF-529C-4FB3-A38E-7741A46BDDC8 Q37141627-1E65245A-4663-4313-BE92-984FD23BBF41 Q37223809-A6E03CCD-BD73-48D5-AB18-EAAFAAF54516 Q37307340-4241074C-61A0-4E43-8270-9DFEE58D163F Q37440765-3F259DB8-00CA-46C5-935C-655627EA83DC Q37972139-17E46B37-08BE-45C5-BCC8-2F39BE617D4A Q37992546-4A2892BA-073E-4F68-B1C4-72F5463D02AA Q38034651-1F4DC9C8-EF30-436E-9DA3-20E6A32A686B Q38134111-3176AE1A-F950-4FC4-912D-2467D8B731D6 Q38523956-6D390922-D35B-4FD5-9C1D-9A6A8D2F4086 Q38575137-9F25E0CB-531E-41BE-8BA6-9A17C6196F41 Q38816367-F022114E-1043-4B49-A4F1-B253AB5BA02F Q39689324-609D6C3F-6561-4CD5-AC5F-AA625C515D62 Q39856408-A5CA041B-D071-4488-8A3A-4C7921766482 Q40367155-D5599992-2891-4397-A773-118230A50F92 Q41709256-22ED437F-C145-48D4-9D8A-25D17F439137 Q42001729-27334553-A3B6-4EC5-AB04-F45B1A827FD8 Q42751498-3C629DC6-2BAA-4CF2-A61B-4622AEDAB4F4 Q43239543-594ABDD7-3A3D-427E-8591-C88F6E09A22F Q44040278-09478E67-F1B0-4529-BC97-8DB01504B226 Q44188699-FD16E4DB-DE7A-4F21-9B48-5A5E17645908 Q46769764-B504D962-9D51-4D01-AE66-59C5821B5469 Q47108799-05B112DA-737C-47ED-8DD3-281E32D78362

P2860

2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity

http://www.wikidata.org/entity/Q27619603

description

1999 nî lūn-bûn

@nan

1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

2.8 A resolution crystal struc ...... h selective antitumor activity

@ast

2.8 A resolution crystal struc ...... h selective antitumor activity

@en

2.8 A resolution crystal struc ...... h selective antitumor activity

@nl

type

label

2.8 A resolution crystal struc ...... h selective antitumor activity

@ast

2.8 A resolution crystal struc ...... h selective antitumor activity

@en

2.8 A resolution crystal struc ...... h selective antitumor activity

@nl

prefLabel

2.8 A resolution crystal struc ...... h selective antitumor activity

@ast

2.8 A resolution crystal struc ...... h selective antitumor activity

@en

2.8 A resolution crystal struc ...... h selective antitumor activity

@nl

P1433

Q27619603-6CA02BB4-3079-4436-AB89-CFAB8C15B214

P1476

Q27619603-1F0550D1-4F9C-4ECB-B069-B96FB4D52055

P2093

Q27619603-46D857F5-13E3-420B-8EBF-3FBFE92CCF47

Q27619603-4828DBAE-4013-465B-9D01-791D9568BEAC

Q27619603-5B784C82-C49C-4487-8628-95B038547596

Q27619603-7B9C7625-2E40-471B-A1C0-6888E8B33AC7

Q27619603-99B9BA94-B6D4-4AF7-A921-0A9ED389C18C

Q27619603-C1B5FA28-DD0F-4C55-B0CB-AA3734B7AAA0

Q27619603-C4AE4E51-67D3-4898-A497-6C6BF5E980DA

Q27619603-C7BE4A09-0D9B-48C9-952E-3018849C82B8

P304

Q27619603-61AFB457-8E36-44D3-AAA7-E58236250DCB

P31

Q27619603-7F2583EB-F2B9-4540-98F2-1DF21B49B7AA

P3181

Q27619603-996A9567-2B85-4DBA-B787-A4EECF39B4B0

P356

Q27619603-963C1DBE-D3A3-4B4A-A866-4B9AE0483436

P407

Q27619603-2A52D930-6B69-48E9-8390-1C89B38F9413

P433

Q27619603-CD26ACE2-B565-48B8-B427-4731C308BD4A

P478

Q27619603-9685EF3D-FC4D-4F8B-A568-FCA757ED9AF7

P577

Q27619603-48681150-D2D8-4017-AEAD-64F4900FC15D

P698

Q27619603-06577BE6-7B01-4FA7-8664-40E67EEF2351

P921

Q27619603-F7FCA769-8B7E-4185-8CA4-9D4E2E9FDA71

P3181

P356

S1074-7613(00)80100-4

P1433

P1476

2.8 A resolution crystal struc ...... h selective antitumor activity

@en

P2093

B H Oh

http://www.w3.org/2001/XMLSchema#string

B J Sung

http://www.w3.org/2001/XMLSchema#string

H C Shin

http://www.w3.org/2001/XMLSchema#string

M S Kim

http://www.w3.org/2001/XMLSchema#string

N K Shin

http://www.w3.org/2001/XMLSchema#string

S S Cha

http://www.w3.org/2001/XMLSchema#string

Y C Sung

http://www.w3.org/2001/XMLSchema#string

Y H Choi

http://www.w3.org/2001/XMLSchema#string

P304

253-61

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3765489

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/S1074-7613(00)80100-4

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

1999-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10485660

http://www.w3.org/2001/XMLSchema#string

P921

crystal structure